UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~March~~April 91, 2026

CORBUS PHARMACEUTICALS HOLDINGS, INC.

(Exact name of Registrant as Specified in Its Charter)


Delaware	001-37348	46-4348039
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

500 River Ridge Drive
Norwood, Massachusetts		02062
(Address of Principal Executive Offices)		(Zip Code)

     Registrant’s Telephone Number, Including Area Code: (617) 963-0100

    

     Not Applicable

    

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	CRBP	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 25.02 ~~Results~~Departure of ~~Operations~~Directors ~~and~~or ~~Financial~~Certain ~~Condition~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 1, 2026, Corbus Pharmaceuticals Holdings, Inc. (the “Company”) ~~issued~~was anotified ~~press~~by ~~release~~Dominic ~~on March 9~~Smethurst, ~~2026, disclosing financial information and operating metrics for its fiscal year ended December 31, 2025 and discussing its business outlook. A copy of~~ the Company’s ~~press~~Chief ~~release~~Medical isOfficer, ~~attached~~of ashis ~~Exhibit~~resignation, ~~99.1~~effective toJune ~~this~~30, ~~Current Report on Form 8-K and is incorporated herein by reference~~2026.

Item 7.01 Regulation FD Disclosure.

~~See~~On April 7, 2026, the Company issued a press release announcing broad alignment with the U.S. Food and Drug Administration (“~~Item~~FDA”) 2on the registration path for CRB-701, the Company’s next-generation, highly stable Nectin-4 targeting antibody drug conjugate (“ADC”), in second-line head and neck squamous cell carcinoma (“HNSCC”) and cervical cancer, with registrational study designs intended to support potential accelerated approval.02 ~~Results~~A copy of ~~Operations~~the press release is furnished as Exhibit 99.1 and ~~Financial~~is ~~Condition”~~incorporated ~~above~~herein by reference.

The ~~Company~~information ~~also~~in ~~updated~~this ~~its~~Current ~~presentation~~Report ~~used~~on byForm ~~management~~8-K tounder ~~describe~~Item ~~its~~7.01, ~~business~~including the information contained in Exhibits 99.1, is Abeing ~~copy~~furnished to the Securities and Exchange Commission (the “SEC”), and shall not be deemed to be “filed” for the purposes of Section 18 of the ~~presentation~~Securities isExchange ~~furnished~~Act of 1934, as ~~Exhibit~~amended ~~99.2~~(the “Exchange Act”), or otherwise subject to the liabilities of that section, and isshall not be deemed to be incorporated ~~herein~~by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.

~~The~~Item ~~information in this Current Report on Form~~ 8~~-K under Items 2~~.~~02 and 7.~~01, ~~including~~Other ~~the information contained in Exhibit 99~~Events.1 and 99.2, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by a specific reference in such filing.

On April 7, 2026, the Company announced broad alignment with the FDA on the registration path for CRB-701, the Company’s next-generation, highly stable Nectin-4 targeting ADC, in HNSCC and cervical cancer.

The agreed upon second-line registrational study designs for CRB-701 include:

•

HNSCC: a single, randomized controlled study exploring the efficacy and safety of CRB-701 compared to physicians’ choice chemotherapy with potential accelerated approval using objective response rate (ORR) as the primary endpoint and potential full approval granted on overall survival (OS) benefit.

•

Cervical cancer: a single, randomized controlled study exploring the efficacy and safety of CRB-701 compared to physicians’ choice of chemotherapy or Tivdak® with potential accelerated approval using ORR as the primary endpoint and potential full approval granted on OS benefit.

•

Continued interactions with the FDA planned to finalize the protocols and statistical analysis plans for the registrational studies.

Item 9.01 Financial Statements and Exhibits.

(d) ~~The following exhibit is furnished with this report~~Exhibits:

Exhibit No.		Description
99.1		Press Release ~~issued by Corbus Pharmaceuticals Holdings, Inc.~~ dated ~~March~~April 97, 2026.
99.2		Investor Presentation
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			Corbus Pharmaceuticals Holdings, Inc.
Date:	~~March~~April 97, 2026	By:	/s/ Yuval Cohen
			Name: Yuval CohenTitle: Chief Executive Officer

Filing Compare · Corbus Pharmaceuticals Holdings, Inc.